Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG101 + Reirradiation in Recurrent Glioblastoma
NCT01071837Phase 2Completed
- Sponsor
- Apogenix
- Start
- Dec 2009
- Primary completion
- Oct 2014
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of asunercept in glioblastoma (GBM) (2 arms), sponsored by Apogenix. Primary endpoint: 6 Months Rate of Progression Free Survival. Started Dec 2009; status: completed.
02
Drugs
asunercept
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01071837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01071837.